FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377246208> ?p ?o ?g. }

• W4377246208 abstract "Abstract Introduction Peyronie’s disease (PD), estimated to affect around 10% of the male population, is an acquired disorder of penile fibrotic tissue. The only FDA approved medical treatment for PD is Intralesional Collagenase Clostridium Histolyticum (CCh). CCh is a mixture of AUX1 and AUXII, two different forms of collagenase that cleave collage type I and type III, leading to plaque degradation. PD plaques, however, also contain fibrin and calcium which CCh is unable to digest. It is unknown if plaque calcification prevents collagenolysis with CCh. Objective To determine if calcification prevents collageolysis of PD plaques with CCh. Methods Calcified PD plaques were collected from five males undergoing excision and grafting for PD. Control tissue was collected from five males undergoing penile implant surgery for erectile dysfunction, with no known history of PD. Tissue samples were then divided into equal weights and incubated with CCh or PBS for 24 hours. The CCh or PBS was injected into the tissue (control or plaque) to mimic administration of CCH for treatment of PD. Following incubation, the fluid (CCh or PBS) was measured for soluble collagen amount and tissue was subjected to Picrosirius Red and H&E staining. Results There was a higher concentration of soluble collagen in the tissue (control and plaque) incubated in CCh (301ug, SD 21.1) compared to the issue incubated in PBS (32.5ug, SD 3.7) (p=0.02). Additionally, there was less type 1 and 3 collagen present in the CCh condition (mean 0.12, SD=0.08), when compared to the PBS condition (0.44, SD=0.17) (p=0.002). However, when comparing within the CCh condition to look at differences between tissue types (calcified vs. control) no differences were found. There was a similar amount of soluble collagen in the CCh control condition (316ug, SD 35) and the CCh calcified condition (286ug, SD 11) (p=0.06). Similarly, the PBS control condition (30ug, SD17) and the PBS calcified condition (35ug, SD 48) were found to have no significant differences in collagen concentration (p=0.4). Finally, there were no significant differences found in type I/III collagen staining between tissues in the CCh condition, with control (0.08, SD=0.02) and calcified (0.17, SD=0.09) demonstrating no significant difference (p=0.08). Tissues in the PBS condition, control (0.5, SD=0.23) and calcified (0.39, SD=0.39), similarly were not significant (p=0.2) (table 1). Conclusions CCh is capable of breaking down collagen in calcified plaques. Further research into CCh as a treatment option for PD calcified plaques is necessary. Disclosure Yes, this is sponsored by industry/sponsor: Endo Pharmaceuticals Clarification Industry funding only - investigator initiated and executed study Any of the authors act as a consultant, employee or shareholder of an industry for: Acerus Pharmaceuticals, Boston Scientific, Coloplast, Endo Pharmaceuticals, Empower Pharmacy, Nestle Health, Olympus, Hims, Inc." @default.
• W4377246208 created "2023-05-23" @default.
• W4377246208 creator A5025348800 @default.
• W4377246208 creator A5040407178 @default.
• W4377246208 creator A5045254927 @default.
• W4377246208 creator A5069428138 @default.
• W4377246208 creator A5071253043 @default.
• W4377246208 date "2023-05-01" @default.
• W4377246208 modified "2023-10-16" @default.
• W4377246208 title "(158) In Vitro Efficacy of Intralesional Collagenase Clostridium Histolyticum for the Treatment of Calcified Peyronie’s Disease Plaques" @default.
• W4377246208 doi "https://doi.org/10.1093/jsxmed/qdad060.153" @default.
• W4377246208 hasPublicationYear "2023" @default.
• W4377246208 type Work @default.
• W4377246208 citedByCount "0" @default.
• W4377246208 crossrefType "journal-article" @default.
• W4377246208 hasAuthorship W4377246208A5025348800 @default.
• W4377246208 hasAuthorship W4377246208A5040407178 @default.
• W4377246208 hasAuthorship W4377246208A5045254927 @default.
• W4377246208 hasAuthorship W4377246208A5069428138 @default.
• W4377246208 hasAuthorship W4377246208A5071253043 @default.
• W4377246208 hasBestOaLocation W43772462081 @default.
• W4377246208 hasConcept C126894567 @default.
• W4377246208 hasConcept C141071460 @default.
• W4377246208 hasConcept C142724271 @default.
• W4377246208 hasConcept C181199279 @default.
• W4377246208 hasConcept C185592680 @default.
• W4377246208 hasConcept C203014093 @default.
• W4377246208 hasConcept C25642318 @default.
• W4377246208 hasConcept C2775930297 @default.
• W4377246208 hasConcept C2777786686 @default.
• W4377246208 hasConcept C2778394429 @default.
• W4377246208 hasConcept C2779145901 @default.
• W4377246208 hasConcept C2779851118 @default.
• W4377246208 hasConcept C2780309369 @default.
• W4377246208 hasConcept C2780644872 @default.
• W4377246208 hasConcept C2908647359 @default.
• W4377246208 hasConcept C54173615 @default.
• W4377246208 hasConcept C55493867 @default.
• W4377246208 hasConcept C71924100 @default.
• W4377246208 hasConcept C99454951 @default.
• W4377246208 hasConceptScore W4377246208C126894567 @default.
• W4377246208 hasConceptScore W4377246208C141071460 @default.
• W4377246208 hasConceptScore W4377246208C142724271 @default.
• W4377246208 hasConceptScore W4377246208C181199279 @default.
• W4377246208 hasConceptScore W4377246208C185592680 @default.
• W4377246208 hasConceptScore W4377246208C203014093 @default.
• W4377246208 hasConceptScore W4377246208C25642318 @default.
• W4377246208 hasConceptScore W4377246208C2775930297 @default.
• W4377246208 hasConceptScore W4377246208C2777786686 @default.
• W4377246208 hasConceptScore W4377246208C2778394429 @default.
• W4377246208 hasConceptScore W4377246208C2779145901 @default.
• W4377246208 hasConceptScore W4377246208C2779851118 @default.
• W4377246208 hasConceptScore W4377246208C2780309369 @default.
• W4377246208 hasConceptScore W4377246208C2780644872 @default.
• W4377246208 hasConceptScore W4377246208C2908647359 @default.
• W4377246208 hasConceptScore W4377246208C54173615 @default.
• W4377246208 hasConceptScore W4377246208C55493867 @default.
• W4377246208 hasConceptScore W4377246208C71924100 @default.
• W4377246208 hasConceptScore W4377246208C99454951 @default.
• W4377246208 hasIssue "Supplement_1" @default.
• W4377246208 hasLocation W43772462081 @default.
• W4377246208 hasOpenAccess W4377246208 @default.
• W4377246208 hasPrimaryLocation W43772462081 @default.
• W4377246208 hasRelatedWork W1524856933 @default.
• W4377246208 hasRelatedWork W1917946443 @default.
• W4377246208 hasRelatedWork W2016993793 @default.
• W4377246208 hasRelatedWork W2342111986 @default.
• W4377246208 hasRelatedWork W2396232949 @default.
• W4377246208 hasRelatedWork W2416700840 @default.
• W4377246208 hasRelatedWork W2997150121 @default.
• W4377246208 hasRelatedWork W3136130821 @default.
• W4377246208 hasRelatedWork W4377246208 @default.
• W4377246208 hasRelatedWork W90635772 @default.
• W4377246208 hasVolume "20" @default.
• W4377246208 isParatext "false" @default.
• W4377246208 isRetracted "false" @default.
• W4377246208 workType "article" @default.